Core Points - The company has completed the change registration of its "Drug Production License" and obtained the new license from the Hunan Provincial Drug Administration [1][2] - The changes include the addition of new production ranges for tablets and raw materials, as well as the acceptance of commissioned production for specific products [1][3] - The new license will not significantly impact the company's existing production structure or current performance [3] Summary of Changes - The production address at 789 Lushong Road, Changsha, Hunan, has added a new production range for tablets, which will only be used for registration purposes [1] - The raw material production facility at 368 Huanglong Road, Tongguan Town, has added new raw materials for registration, including Remdesivir and others [1] - The company will produce Huangtengsu dispersible tablets and Jingangteng dispersible tablets under commission from Hunan Xiangya Pharmaceutical Co., Ltd. [1] - The company will also produce Yinhuang granules under commission from Hunan Ruixin Pharmaceutical Co., Ltd. [1] Impact on the Company - The changes in the "Drug Production License" will not affect the company's existing production capacity, which will remain stable [3] - The company does not expect any significant impact on its current performance due to the new license [3] Product Inclusion in National Medical Insurance - The company's product, Yinxue Qufeng Zhitong Granules, has been included in the 2025 National Medical Insurance Directory, which is expected to enhance its market promotion and sales potential [5][7] - This product is based on a traditional Chinese medicine formula and has not yet been officially launched for sale [6][7] - The company aims to strengthen its position in the market by increasing investment in the research and development of innovative Chinese medicine products [7]

Group 1: Core Views - Hunan Fangsheng Pharmaceutical Co., Ltd. announced that its innovative traditional Chinese medicine, Yangxue Qufeng Zhitong Granules, has been included in the National Medical Insurance Directory for 2025, which is expected to enhance market promotion and sales scale [1][3] - The product is based on a modified formula of a well-known traditional Chinese medicine and aims to supplement qi and nourish blood while alleviating pain [1][2] Group 2: Drug Sales Situation - Yangxue Qufeng Zhitong Granules, classified as a Category 1 innovative traditional Chinese medicine, was approved for listing on June 9, 2025, but has not yet officially commenced sales [2] Group 3: Impact on the Company - The inclusion of Yangxue Qufeng Zhitong Granules in the medical insurance directory is anticipated to positively impact the company's future operating performance and market share, although it will not have a significant short-term effect [3] - The company has a strategic goal to become a health industry group centered on innovative traditional Chinese medicine, with plans to increase investment in research and market cultivation [3]